Serotonin-Dopamine Interaction: Experimental Evidence and Therapeutic Relevance
- 1st Edition, Volume 172 - September 26, 2008
- Imprint: Elsevier Science
- Editors: Giuseppe Di Giovanni, Vincenzo Di Matteo, Ennio Esposito
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 4 - 5 3 2 3 5 - 0
- eBook ISBN:9 7 8 - 0 - 0 8 - 0 9 3 2 6 8 - 2
This book provides a unique and timely multidisciplinary synthesis of our current knowledge of the anatomy, pharmacology, physiology and behavioral data of the serotonin… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteThis book provides a unique and timely multidisciplinary synthesis of our current knowledge of the anatomy, pharmacology, physiology and behavioral data of the serotonin (5-HT)-dopamine (DA) interactions. Central serotonergic and dopaminergic systems play a critical role in the regulation of normal and abnormal behaviors. Moreover, recent evidence suggests that the dysfunction of the DA and 5-HT neurotransmitter systems contribute to various mental disorders including depression, schizophrenia, drug addiction and Parkinson’s disease. This extremely important topic is of wide interest within the scientific community, with relevance not only to specialists but also to general practitioners and students. The book provides a valuable contribution to the debate on new pharmacological approaches for several psychopathological states, with contributions from expert neuroscientists and pharmacologists who comprehensively survey the most significant currently active areas of dopamine/serotonin interactions.
- Provides an understanding of the interaction between Serotonin and Dopamine
- Appeals equally to specialists, general practitioners, students and researchers
- Contributes to the debate on new pharmacological approaches to several psychopathological states
- Gives a comprehensive anatomical description plus the physiology and pharmacology of dopaminergic and serotonergic systems
- Singles out neuropsychiatric and suggests new therapeutic approaches
Clinical Psychiatrists, Primary Care Physicians, and specialists in the behavioral health community. Also Graduate students and researchers involved with serotonergic and dopaminergic systems. Possibly Pharmaceutical companies who market dopaminergic and serotonergic drugs
1. SEROTONIN-DOPAMINE INTERACTIONS IN THE CENTRAL NERVOUS SYSTEM
1. Serotonin-Dopamine Interaction: an overview
E. Esposito, V. Di Matteo and G. Di Giovanni (Santa Maria Imbaro, Chieti and Palermo, Italy)
2. Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies
V. Di Matteo, G. Di Giovanni, M. Pierucci and E. Esposito (Santa Maria Imbaro, Chieti and Palermo, Italy)
3. Serotonin-Dopamine Interaction: electrophysiological evidence
G. Di Giovanni, V. Di Matteo, M. Pierucci and E. Esposito (Palermo and Santa Maria Imbaro, Chieti, Italy
4. Functional genetic polymorphisms in serotonin and dopamine gene systems and their significance in behavioural disorders
U.M. D’Souza and I.W. Craig (London, UK)
2. SEROTONIN-DOPAMINE INTERACTIONS IN SCHIZOPHRENIA
5. Distribution of 5-HT and DA receptors in primate prefrontal cortex: implications for pathophysiology and treatment
J. de Almeida, J.M. Palacios and G. Mengod (Barcelona, Spain)
6. Alterations of dopamine and serotonin transmission in schizophrenia
G. Remington (Toronto, ON, Canada)
7. Serotonin and dopamine interactions in psychosis prevention
N.M. Richtand and R.K. McNamara (Cincinnati, OH, USA)
8. Role of serotonin and dopamine receptor binding in antipsychotic efficacy
N.M. Richtand, J.A. Welge, A.D. Logue, P.E. Keck, Jr., S.M. Strakowski and R.K. McNamara (Cincinnati, OH, USA)
9. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems
H.Y. Meltzer and M. Huang (Nashville, TN, USA)
10. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis
T. Kuroki, N. Nagao and T. Nakahara (Kanzaki, Japan)
11. Serotonin-dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders
M.D. Wood and P.W. Wren (Harlow, UK)
3. SEROTONIN-DOPAMINE INTERACTIONS IN DEPRESSION
12. The dorsal raphe nucleus and serotonin —implications for neuroplasticity linked to major depression and Alzheimer’s disease
K.A. Michelsen, J. Prickaerts and H.W.M. Steinbusch (Maastricht, The Netherlands)
13. Dynamics of the dopaminergic system as a key component to the understanding of depression
G. Yadid and A. Friedman (Ramat-Gan, Israel)
14. Physiological and therapeutic relevance of constitutive activity of 5-HT2A and 5-HT2C receptors for the treatment of depression
K.A. Berg, J.A. Harvey, U. Spampinato and W.P. Clarke (San Antonio, TX, Philadelphia, PA, USA and Bordeaux, France)
15. The role of dopamine and serotonin in suicidal behaviour and aggression
E. Ryding, M. Lindström and L.Träskman-Bendz (Stockholm, Sweden)
4. SEROTONIN-DOPAMINE INTERACTIONS IN DRUG ADDICTION
16. Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse
M.J. Bubar and K.A. Cunningham (Galveston, TX, USA)
17. Pharmacological inhibition of dopamine- and serotonin activity blocks spontaneous and cocaine-activated behaviour
R.J. Carey, J.P. Huston and C.P. Müller (Dusseldorf, Germany and London, UK)
18. Serotonin receptors as potential targets for modulation of nicotine use and dependence
P.J. Fletcher, A. Dzung Lê and G.A. Higgins (Toronto, ON, Canada)
19. Dopamine/Serotonin releasers as medications for stimulant addictions
R.B. Rothman, B.E. Blough and M.H. Baumann (Baltimore, MD and Triangle Park, NC, USA)
20. PTEN-5-HT2C coupling: A new target for treating drug addiction
J.-C. Maillet, Y. Zhang, X. Li, X. Zhang (Ottawa, ON, Canada)
5. SEROTONIN-DOPAMINE INTERACTIONS IN MOTOR DISORDERS
21. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson’s disease and other motor disorders
V. Di Matteo, M. Pierucci, E. Esposito, G. Crescimanno, A. Benigno and G. Di Giovanni (Santa Maria Imbaro, Chieti, and Palermo, Italy)
22. Serotonin-Dopamine interaction in the induction and maintenance of LDOPA-induced dyskinesias
M. Carta, T. Carlsson, A. Muňoz, D. Kirik and A. Björklund (Lund, Sweden)
23. Parkinson’s disease – opportunities for novel therapeutics to reduce the problems of levodopa therapy
S.H. Fox, R. Chuang and J.M. Brotchie (Toronto, ON, Canada)
24. Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome
1. Serotonin-Dopamine Interaction: an overview
E. Esposito, V. Di Matteo and G. Di Giovanni (Santa Maria Imbaro, Chieti and Palermo, Italy)
2. Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies
V. Di Matteo, G. Di Giovanni, M. Pierucci and E. Esposito (Santa Maria Imbaro, Chieti and Palermo, Italy)
3. Serotonin-Dopamine Interaction: electrophysiological evidence
G. Di Giovanni, V. Di Matteo, M. Pierucci and E. Esposito (Palermo and Santa Maria Imbaro, Chieti, Italy
4. Functional genetic polymorphisms in serotonin and dopamine gene systems and their significance in behavioural disorders
U.M. D’Souza and I.W. Craig (London, UK)
2. SEROTONIN-DOPAMINE INTERACTIONS IN SCHIZOPHRENIA
5. Distribution of 5-HT and DA receptors in primate prefrontal cortex: implications for pathophysiology and treatment
J. de Almeida, J.M. Palacios and G. Mengod (Barcelona, Spain)
6. Alterations of dopamine and serotonin transmission in schizophrenia
G. Remington (Toronto, ON, Canada)
7. Serotonin and dopamine interactions in psychosis prevention
N.M. Richtand and R.K. McNamara (Cincinnati, OH, USA)
8. Role of serotonin and dopamine receptor binding in antipsychotic efficacy
N.M. Richtand, J.A. Welge, A.D. Logue, P.E. Keck, Jr., S.M. Strakowski and R.K. McNamara (Cincinnati, OH, USA)
9. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems
H.Y. Meltzer and M. Huang (Nashville, TN, USA)
10. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis
T. Kuroki, N. Nagao and T. Nakahara (Kanzaki, Japan)
11. Serotonin-dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders
M.D. Wood and P.W. Wren (Harlow, UK)
3. SEROTONIN-DOPAMINE INTERACTIONS IN DEPRESSION
12. The dorsal raphe nucleus and serotonin —implications for neuroplasticity linked to major depression and Alzheimer’s disease
K.A. Michelsen, J. Prickaerts and H.W.M. Steinbusch (Maastricht, The Netherlands)
13. Dynamics of the dopaminergic system as a key component to the understanding of depression
G. Yadid and A. Friedman (Ramat-Gan, Israel)
14. Physiological and therapeutic relevance of constitutive activity of 5-HT2A and 5-HT2C receptors for the treatment of depression
K.A. Berg, J.A. Harvey, U. Spampinato and W.P. Clarke (San Antonio, TX, Philadelphia, PA, USA and Bordeaux, France)
15. The role of dopamine and serotonin in suicidal behaviour and aggression
E. Ryding, M. Lindström and L.Träskman-Bendz (Stockholm, Sweden)
4. SEROTONIN-DOPAMINE INTERACTIONS IN DRUG ADDICTION
16. Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse
M.J. Bubar and K.A. Cunningham (Galveston, TX, USA)
17. Pharmacological inhibition of dopamine- and serotonin activity blocks spontaneous and cocaine-activated behaviour
R.J. Carey, J.P. Huston and C.P. Müller (Dusseldorf, Germany and London, UK)
18. Serotonin receptors as potential targets for modulation of nicotine use and dependence
P.J. Fletcher, A. Dzung Lê and G.A. Higgins (Toronto, ON, Canada)
19. Dopamine/Serotonin releasers as medications for stimulant addictions
R.B. Rothman, B.E. Blough and M.H. Baumann (Baltimore, MD and Triangle Park, NC, USA)
20. PTEN-5-HT2C coupling: A new target for treating drug addiction
J.-C. Maillet, Y. Zhang, X. Li, X. Zhang (Ottawa, ON, Canada)
5. SEROTONIN-DOPAMINE INTERACTIONS IN MOTOR DISORDERS
21. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson’s disease and other motor disorders
V. Di Matteo, M. Pierucci, E. Esposito, G. Crescimanno, A. Benigno and G. Di Giovanni (Santa Maria Imbaro, Chieti, and Palermo, Italy)
22. Serotonin-Dopamine interaction in the induction and maintenance of LDOPA-induced dyskinesias
M. Carta, T. Carlsson, A. Muňoz, D. Kirik and A. Björklund (Lund, Sweden)
23. Parkinson’s disease – opportunities for novel therapeutics to reduce the problems of levodopa therapy
S.H. Fox, R. Chuang and J.M. Brotchie (Toronto, ON, Canada)
24. Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome
- Edition: 1
- Volume: 172
- Published: September 26, 2008
- No. of pages (Hardback): 688
- No. of pages (eBook): 688
- Imprint: Elsevier Science
- Language: English
- Hardback ISBN: 9780444532350
- eBook ISBN: 9780080932682
GD
Giuseppe Di Giovanni
Prof. Giuseppe Di Giovanni received his Ph.D. in Neuroscience from the University of Chieti, Italy and was a postdoctoral fellow at Yale University, USA. Previously Senior Lecturer of Human Physiology at the Faculty of Medicine and Surgery, University of Palermo, and Associate Professor at the University of Malta, from 2013 he is Professor of Human Physiology at the Medical School of the University of Malta and from 2018 Honorary Professor at Cardiff University, UK. His research focuses on understanding the pathophysiology of monoaminergic systems using electrophysiological and neurochemical approach. He has published more than 120 peer-reviewed papers, edited 7 books and 6 special issues of various journals.
Affiliations and expertise
University of Malta, MaltaVD
Vincenzo Di Matteo
Affiliations and expertise
Istituto di Ricerche Farmacologiche Mario Negri, ItalyEE
Ennio Esposito
Affiliations and expertise
Istituto di Ricerche Farmacologiche Mario Negri, ItalyRead Serotonin-Dopamine Interaction: Experimental Evidence and Therapeutic Relevance on ScienceDirect